Effects of the early administration of heparin in patients with ST-elevation myocardial infarction treated by primary angioplasty

Circulation Journal

Volumn 71, Issue 6, 2007, Pages 862-867

  Chung, Woo Young ^a,b   Han, Mi Jung ^a   Cho, Young Seok ^a,b   Kim, Kwang Il ^b   Chang, Hyuk Jai ^a,b   Youn, Tae Jin ^a,b   Chae, In Ho ^a,b   Choi, Dong Ju ^a,b   Kim, Cheol Ho ^a,b   Oh, Byung Hee ^b   Park, Young Bae ^b   Choi, Yun Shik ^b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Acute myocardial infarction; Angioplasty; Heparin; Patency

Indexed keywords

ENOXAPARIN; HEPARIN;

ADULT; ANGIOGRAPHY; ANGIOPLASTY; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CONTROLLED STUDY; EMERGENCY WARD; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; TREATMENT OUTCOME; VASCULAR PATENCY;

ANGIOPLASTY, BALLOON; ANTICOAGULANTS; ENOXAPARIN; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34249725091     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.862     Document Type: Article

References (18)

1. Keeley EC, Grines CL. Primary coronary intervention for acute myocardial infarction. JAMA 2004; 291: 736-739.
2. Brodie BR, Stone GW, Cox DA, Stuckey TD, Turco M, Tcheng JE, et al. Impact of treatment delays on outcomes of primary percutaneous coronary intervention for acute myocardial infarction: Analysis from the CADILLAC trial. Am Heart J 2006; 151: 1231-1238.
3. Antman EM. The search for replacements for unfractionated heparin. Circulation 2001; 103: 2310-2314.
4. Agnelli G, Borm J, Cosmi B, Levi M, Ten Cate JW. Effects of standard heparin and a low molecular heparin (Kabi 2165) on fibrinolysis. Thromb Haemost 1988; 60: 311-313.
5. De Bono DP, Simoons ML, Tijssen J, Arnold AE, Betriu A, Burgersdijk C, et al. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: Results of a randomised double blind European Cooperative study group trial. Br Heart J 1992; 67: 122-128.
6. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-1622.
7. Verheugt FWA, Liem A, Zijlstra F, Marsh RC, Veen G, Bronzwaer JGF. High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: Results of the Heparin in Early Patency (HEAP) pilot study. J Am Coll Cardiol 1998; 31: 289-293.
8. Liem A, Zijlstra F, Ottervanger JP, Hoorntje JCA, Suryapranata H, De Boer MJ, et al. High dose heparin as pretreatment for primary angioplasty in acute myocardial infarction: The Heparin in Early Patency (HEAP) randomized trial. J Am Coll Cardiol 2000; 35: 600-604.
9. Zijlstra F, Ernst N, De Boer MJ, Nibbering E, Suryapranata H, Hoorntje JCA, et al. Influence of prehospital administration of aspirin and heparin on initial patency of the infarct-related artery in patients with acute ST elevation myocardial infarction. J Am Coll Cardiol 2002; 39: 1733-1737.
10. Labeque JN, Jais C, Dubos O, Denard M, Berhouet M, Leroux L, et al. Prehospital administration of enoxaparin before primary angioplasty for ST-elevation acute myocardial infarction. Catheter Cardiovasc Interv 2006; 67: 207-213.
11. Antman EM, Giugliano RP, Gibson CM, McCabe CH, Coussement P, Kleiman NS, et al. Abciximab facilitates the rate and extent of thrombolysis results of the Thrombolysis In Myocardial Infarction (TIMI) 14 trial. Circulation 1999; 99: 2720-2732.
12. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, et al. Thrombolysis in myocardial infarction (TIMI) trial. Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987; 76: 142-154.
13. Yip HK, Chen MC, Chang HW, Hang CL, Hsieh YK, Fang CY, et al. Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: Predictors of slow-flow and no-reflow phenomenon. Chest 2002; 122: 1322-1332.
14. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol 2004; 44: 671-719.
15. Cura FA, L'Allier PL, Kapadia SR, Houghtaling PL, Dipaola LM, Topol EJ, et al. Predictors and prognosis of suboptimal coronary blood flow after primary coronary angioplasty in patients with acute myocardial infarction. Am J Cardiol 2001; 88: 124-128.
16. Fujiwara K, Hiasa Y, Takahashi T, Yamaguchi K, Ogura R, Ohara Y, et al. Influence of diabetes mellitus on outcome in the era of primary stenting for acute myocardial infarction. Circ J 2002; 66: 800-804.
17. Addala S, Grines CL, Dixon SR, Stone GW, Boura JA, Ochoa AB, et al. Predicting mortality in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention (PAMI risk score). Am J Cardiol 2004; 93: 629-632.
18. Halkin A, Singh M, Nikolsky E, Grines CL, Tcheng JE, Garcia E, et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: The CADILLAC risk score. J Am Coll Cardiol 2005; 45: 1397-1405.